Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates
06:15pm, Thursday, 12'th Feb 2026
Ultragenyx (RARE) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.2. This compares to a loss of $1.39 per share a year ago.
NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE) of a class action securities lawsu
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
04:01pm, Thursday, 12'th Feb 2026
2025 total revenue of $673 million, Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million
RARE Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. (RARE)
12:37pm, Thursday, 12'th Feb 2026
Did you buy RARE common stock between August 3, 2023, and December 26, 2025? Affected Ultragenyx Pharmaceutical Inc. Investor Summary Who: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) What: Securitie
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors
12:36pm, Thursday, 12'th Feb 2026
LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ultragenyx Pharmaceutical, Inc., (“Ultragenyx” or the "Company") (NASDAQ: RARE) investors of a class action on behalf o
NEW ORLEANS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securi
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
10:06pm, Wednesday, 11'th Feb 2026
NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical I
Did you buy RARE common stock between August 3, 2023, and December 26, 2025? Affected Ultragenyx Pharmaceutical Inc. Investor Summary Who: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) What: Securitie
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Wednesday, 11'th Feb 2026
New class action for Ultragenyx (RARE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/6/2026.
Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Filed; Lead Plaintiff Deadline April 6, 2026 – RGRD Law
11:30am, Wednesday, 11'th Feb 2026
SAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE) on behalf of purchasers or acquirers of Ultragenyx
ATTENTION: RARE INVESTORS: Contact Berger Montague About an Ultragenyx Pharmaceutical Inc. Class Action Lawsuit
10:11am, Wednesday, 11'th Feb 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - February 11, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutic
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acqui
Levi & Korsinsky Notifies Shareholders of Ultragenyx Pharmaceutical Inc.(RARE) of a Class Action Lawsuit and an Upcoming Deadline
09:00am, Wednesday, 11'th Feb 2026
NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE) of a class action securities lawsuit.
NEW YORK CITY and NEW ORLEANS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in U
RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities fraud class action lawsuit has been filed against Ultragenyx Pharmace
